Mar 31, 2013
IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation.
Mar 07, 2013
Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.
Feb 13, 2013
IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.
Jan 20, 2013
IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.
Dec 26, 2012
IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.
Dec 16, 2012
Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing.